Becaplermin: Recombinant platelet derived growth factor, a new treatment for healing diabetic foot ulcers

Expert Opinion on Biological Therapy

Volumn 2, Issue 2, 2002, Pages 211-218

  Nagai, Mary K ^a   Embil, John M ^a  

^a HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Becaplermin; Diabetic foot ulcer; Recombinant platelet derived growth factor; Regranex; rh PDGF BB

Indexed keywords

BECAPLERMIN; CARBOXYMETHYLCELLULOSE; GROWTH FACTOR; RECOMBINANT PLATELET DERIVED GROWTH FACTOR; RECOMBINANT PLATELET DERIVED GROWTH FACTOR BB; ANTICOAGULANT AGENT; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR BB; PLATELET-DERIVED GROWTH FACTOR BB; RECOMBINANT PROTEIN;

CLINICAL TRIAL; DIABETIC FOOT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FOOT ULCER; HUMAN; REVIEW; ULCER HEALING; WOUND CARE; ANIMAL; CHEMISTRY; DRUG EFFECT; WOUND HEALING;

ANIMALIA; INSERTION SEQUENCES; SACCHAROMYCES; SACCHAROMYCES CEREVISIAE;

ANIMALS; ANTICOAGULANTS; DIABETIC FOOT; HUMANS; PLATELET-DERIVED GROWTH FACTOR; RECOMBINANT PROTEINS; WOUND HEALING;

EID: 0035989750     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2.2.211     Document Type: Review

References (53)

1. Global burden of diabetes 1995-2025: Prevalence, numerical estimates and projections
2. The health of Canadians with diabetes
3. The prevalence and incidence of diabetes mellitus United States, 1980-1987
4. 1988 Clinical practice guidelines for the management of diabetes in Canada
5. Trends in diabetes and diabetic complications, 1980-1987
6. The burden of chronic hyperglycemia
7. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
8. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional therapy and the risk of complications in patients with Type 2 diabetes (UKPDS 33)
9. Effect of intensive blood - Glucose control with metformin on complications in overweight patients with Type 2 diabetes (UKPDS 34)
10. The burden of diabetic foot ulcers
11. The economic cost of non-insulin dependent diabetes mellitus
12. The diabetic foot
13. Physiology of the chronic wound
14. Pressure ulcer prevalence, incidence, risk factors and impact
15. Chronic leg ulcers: An underestimated problem in primary health care among elderly patients
16. Pathways to diabetic limb amputation. Basis for prevention
17. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers
18. Lawrence Lecture. The diabetic foot: Neuropathic in aetiology?
19. The dysvascular foot: A system for diagnosis and treatment
20. Outpatient diagnosis and care of the diabetic foot
21. Chronic foot wounds in diabetics and total contact casting
22. Foundations of good ulcer care
23. Wound infection. A failure of wound healing caused by an imbalance of bacteria
24. Growth factors and wound healing: Part II. Role in normal and chronic wound healing
25. Wound healing-aiming for perfect skin regeneration
26. Physiology and healing dynamics of chronic cutaneous wounds
27. Cutaneous wound healing
28. Becaplermin (Regranex® gel 0.01%): Recombinant platelet-derived growth factor (rh-PDGF-BB) for healing diabetic foot ulcers
29. The effect of chronic wound fluid on cell proliferation in vitro
30. Human wound fluid from acute wounds stimulates fibroblast and endothelial cell growth
31. Determination of endogenous cytokines in chronic wounds
32. The role of growth factors in the healing of chronic wounds
33. The role of growth factors in wound healing
34. Platelet-derived growth factor
35. Two classes of PDGF receptor recognize different isoforms of PDGE
36. Platelet-derived growth factor
37. In vitro incisional wound healing augmented by platelet-derived growth factor and recombinant c-sis gene homodimeric proteins
38. Preclinical promise of becaplermin (rhPDGF-BB) in wound healing
39. Topical growth factors in wound contraction in the rat Part II. Platelet-derived growth factor and wound contraction in normal and steroid-impaired rats
40. Reversal of impaired wound healing in irradiated rats by platelet-derived growth factor-BB
41. Platelet-derived growth factor and transforming growth factor-beta enhance tissue repair activities by unique mechanisms
42. Tissue generation with growth factors
43. Comparison of pig and guinea pig full and partial thickness skin excision wound models for evaluating the effects of rhPDGF-BB
44. Growth factor-induced acceleration of tissue repair through direct and inductive activities in a rabbit dermal ulcer model
45. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A Phase III randomized placebo-controlled double-blind study
46. Effect of sodium carboxymethylcellulose aqueous-based gel vs. becaplerin gel in patients with non-healing lower extremity diabetic ulcers
47. Clinical efficacy of becaplermin (rh PDGF-BB) gel
48. Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with non-healing, lower extremity diabetic ulcers: A combined analysis of four randomized studies
49. Recombinant human platelet-derived growth factor-BB (becaplermin) for healing chronic lower extremity diabetic ulcers: An open-label clinical evaluation of efficacy
50. Healing of diabetic neuropathic foot ulcers receiving standard treatment in meta-analysis
51. Complications of the lower extremities in persons with diabetes presenting to multi-disciplinary foot clinic
52. Treatment options for diabetic neuropathic foot ulcers: A cost-effectiveness analysis